alexa Catumaxomab treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: A phase II study.
Oncology

Oncology

Chemotherapy: Open Access

Author(s): Berek JS, Edwards RP, Parker L, DeMars LR, Herzog TJ

Abstract Share this page

Background: Malignant ascites (MA) in ovarian carcinoma (OC) patients (pts) is associated with a poor prognosis and reduced quality of life due to symptoms from ascites. In 2009, catumaxomab was approved in the EU for the intraperitoneal (IP) treatment of MA. Methods: In this single-arm, open-label, US, multicenter, phase II study, 32 chemotherapy-refractory and heavily pretreated (median of 4.5 prior chemotherapies) OC pts with MA were treated with catumaxomab. Pts received 4 IP infusions (10, 20, 50, and 150 µg) over 3 hours on days 0, 3, 7, and 10. The primary endpoint was the proportion of pts with at least a 4-fold increase in the puncture-free interval (PuFI) relative to their pretreatment interval. Main secondary endpoints were puncture-free survival (PuFS), overall survival (OS), MA symptoms based on patient-assessed FACIT-AI scores, safety, and tolerability. Results: 22.6% pts achieved at least a 4-fold increase in the PFI after catumaxomab treatment, which was below the predefined threshold of 60%. In median, the PFI was prolonged 2.0 fold in the full-analysis set (from median of 1.7 to 3.9 weeks) and 2.9 fold in the per-protocol set (from median of 2.6 to 7.1 weeks). 19 (59.4%) pts required paracentesis after catumaxomab treatment. The other pts died or were lost to follow up. The median PuFS was 4.2 weeks and median OS was 3.6 months. After catumaxomab treatment, patients’ symptoms improved in the majority of 13 predefined categories or remained stable. At repuncture, most symptoms were still improved compared with screening. The most frequent adverse events, pyrexia, nausea, and vomiting, are related to cytokine release. Transient increases in liver parameters and transient decreases in blood lymphocytes were regularly observed but were generally without clinical relevance. Conclusions: The study demonstrates an overall prolongation of PuFI and improvement of MA symptoms in these heavily pretreated patients. The median OS of 3.6 months support a therapeutic effect of catumaxomab. The safety profile of catumaxomab was acceptable, consistent with its mode of action and similar to that in previous clinical studies.

  • To read the full article Visit
  • Subscription
This article was published in J Clin Oncol and referenced in Chemotherapy: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords